Alpha Cognition Inc. (NASDAQ: ACOG) is making significant strides in the commercial launch of ZUNVEYL, its treatment for Alzheimer's disease, according to an updated coverage report from Stonegate Capital Partners. The company's second-quarter 2026 results exceeded expectations, with net product revenue surging 71% sequentially to $6.0 million, driven by a 37% increase in bottles dispensed to 8,294. June emerged as the strongest demand month since launch, with 2,997 bottles dispensed, and management indicated that growth continued into the third quarter.
The quality of the quarter is particularly noteworthy given that it occurred without material stocking benefits or significant changes in payer implementation. Downstream pharmacy benefit manager (PBM) implementation remained steady at approximately 16%, suggesting that the growth was fueled by underlying demand and improved commercial execution. This indicates that the product is gaining traction in the market, with prescriptions, repeat use, and facility adoption all advancing despite limited formulary access.
Key metrics from the quarter reveal broadening adoption and deepening utilization. The company reported 1,347 quarterly prescribers, with 1,024 repeat prescribers, indicating that physicians are not only trying ZUNVEYL but also continuing to prescribe it. Additionally, 1,908 cumulative writers and 1,095 long-term care (LTC) facilities generated prescriptions during the quarter, showcasing a widening base of demand. With PBM implementation still at a low level, there is substantial room for growth as broader payer access becomes an additional driver.
Alpha Cognition is also balancing its commercial investment with a growing evidence base. The company lowered its full-year 2026 research and development (R&D) and selling, general, and administrative (SG&A) guidance to $50 million to $54 million, while reaffirming its target of achieving operating profitability by 2027. This prudent financial management is supported by several upcoming milestones, including the CONVERGE data expected in the third quarter of 2026, the ongoing RESOLVE study, and the sublingual program, which is gated by comparative pharmacokinetic results.
Stonegate's analysis underscores that the core setup for Alpha Cognition is increasingly about breadth, depth, and payer upside. The white space across homes and physicians remains significant, utilization is deepening, and broader PBM implementation could provide a substantial incremental boost to growth. As the company continues to execute on its commercial strategy and advance its clinical pipeline, the potential for long-term value creation appears promising.
